SCHEMBL2497367

SCHEMBL2497367

O=C(O)CC(CC1CC1)c1cccc(O)c1F

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRB3 P13945 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP12 P39900 1/20 0.34
GABBR2 O75899 1/20 0.33
GABBR1 Q9UBS5 1/20 0.33
OPRM1 P35372 4/20 0.33
OPRK1 P41145 4/20 0.33
P2RX7 Q99572 3/20 0.33
FFAR1 O14842 2/20 0.33
ITGB3 P05106 1/20 0.33
ITGAV P06756 1/20 0.33
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2498590 0.84 ADRB1 (0.41) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL2500479 0.84 ADRB1 (0.41) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL2499280 0.84 ADRB1 (0.41) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL16798073 0.80 ADRB1 (0.40) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL3658574 0.80 ADRB1 (0.45) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL3651803 0.80 ADRB1 (0.45) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL2499881 0.80 ADRB1 (0.45) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL2503690 0.77 FFAR1 (0.49) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL2497359 0.77 ADRB1 (0.43) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL2497872 0.77 ADRB1 (0.43) ADRB1ADRA2AADRB3ADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
EP-2205548-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS Amgen, Inc (US) 2010-07-14 EP disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137561-A1 Substituted biphenyl GPR40 modulators GPR119, GPR65, GPR55 ADRB1 59/4885ADRA2A 129/4885ADRB3 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.